Zicam Case Shows FDA Takes Defining Adverse Events Seriously
This article was originally published in The Tan Sheet
Executive Summary
Narrowly interpreting the definition of serious adverse events - compared to FDA's approach - is already costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products
You may also be interested in...
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
With Nasal Ease U.S. Launch, Hi-Tech Bids For Allergy Relief Market Share
Hi-Tech Pharmacal plans to launch its homeopathic allergy reliever Nasal Ease in the U.S. in a bid to capture some of the market share Matrixx Initiatives lost when it withdrew its intranasal Zicam products.